Irinotecan Liposome is named as a drug or biological intervention in 7 clinical trials in our China trial register, 3 of which are recruiting. Lead sponsors include Second Affiliated Hospital, Zhejiang University, School of Medicine (1), Sir Run Run Shaw Hospital (1) and Shenzhen Majory Biotechnology Co., Ltd. (1). Registered phases: Phase 2, Phase 1/2, Not applicable and Phase 2/3. Conditions studied include Pancreatic Cancer; Colorectal Cancer Metastatic; Biliary Tract Carcinoma.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Pancreatic Cancer | 2 |
| Colorectal Cancer Metastatic | 1 |
| Biliary Tract Carcinoma | 1 |
| Pancreatic Ductal Adenocarcinoma (PDAC) | 1 |
| Adjuvant Therapy | 1 |
| SCLC | 1 |
| Metastatic Colorectal Cancer (CRC) | 1 |
| Liposomal Irinotecan | 1 |
| Second-Line | 1 |
| Lead sponsor | Trials |
|---|---|
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| Sir Run Run Shaw Hospital | 1 |
| Shenzhen Majory Biotechnology Co., Ltd. | 1 |
| Kuirong Jiang | 1 |
| Fudan University | 1 |
| The Second Affiliated Hospital of Dalian Medical University | 1 |
| Hebei Medical University Fourth Hospital | 1 |
| Register | Irinotecan Liposome trials |
|---|---|
| Clinical trials in China | 7 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Irinotecan Liposome works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Irinotecan Liposome (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.